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ABSTRACT
Background: Fondaparinux is an agent that has a well-established 
safety and efficacy profile in the treatment of non-ST segment 
elevation acute coronary syndromes. When used alone, how-
ever, it is associated with a higher incidence of thrombotic 
complications during invasive coronary procedures, requiring 
the supplementation of an anti-IIa agent. This study aimed 
to evaluate the efficacy and safety of percutaneous coronary 
intervention (PCI) in patients with non-ST segment elevation 
acute coronary syndromes that were previously treated with 
fondaparinux. Methods: This was a prospective, controlled reg-
istry, enrolling 127 consecutive patients submitted to an early 
invasive stratification during treatment with fondaparinux with 
the supplementation of intravenous unfractionated heparin at 
a dose of 85 U/kg at the time of PCI. Results: The composite 
primary endpoint rate, including death, acute myocardial 
infarction, stroke, stent thrombosis, or emergency myocardial 
revascularisation was 3.2%. The cumulative incidence of major 
bleeding and vascular complications was 3.2%. There were no 
cases of guide catheter thrombosis or abrupt vessel closure. 
Conclusions: PCI in patients with acute coronary syndromes 
receiving fondaparinux was associated with a low rate of major 
adverse cardiovascular ischaemic events and severe haemor-
rhagic complications. Supplementation with unfractionated 
heparin during the invasive procedures eliminated the risk of 
catheter-related thrombosis.
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RESUMO
Fondaparinux em Intervenção Coronária Percutânea 
no Tratamento da Síndrome Coronária Aguda
Introdução: Considerado um fármaco com adequado perfil de 
eficácia e segurança no tratamento da síndrome coronária aguda 
sem supradesnivelamento do segmento ST, o fonda parinux, 
utilizado de forma isolada, associa se a maior ocorrência de 
complicações trombóticas durante a realização de procedimentos 
coronários invasivos, requerendo a adição de agente com ativi-
dade anti- IIa. Este estudo teve como objetivo avaliar a eficácia 
e a segurança da intervenção coronária percutânea (ICP) em 
pacientes admitidos com diagnóstico de síndrome coronária 
aguda sem supradesnivelamento do seg mento ST, previamente 
tratados com fondaparinux. Métodos: Registro prospectivo, 
controlado, envolvendo 127 pacientes consecutivos submetidos 
a estratificação invasiva precoce na vigência de fondaparinux, 
com suplementação de heparina não fracionada intravenosa 
na dose de 85 U/kg no momento da ICP. Resultados: A taxa 
do desfecho primário, composto por morte, infarto agudo do 
miocárdio, acidente vascular encefálico, trombose de stent ou 
revascularização miocárdica de urgência, foi de 3,2%. A incidên-
cia acumulada de sangramento grave e complicações vasculares 
foi de 3,2%. Não houve casos de trombose do cateter guia ou 
oclusão abrupta do vaso. Conclusões: A ICP em pacientes com 
síndrome coronária aguda em uso de fondaparinux associa se a 
baixas taxas de eventos cardiovasculares adversos isquêmicos e 
de complicações hemorrágicas graves. A suplementação com 
heparina não fracionada durante o procedimento invasivo elimina 
o risco de trombose do cateter.
DESCRITORES: Síndrome coronariana aguda. Angioplastia. 
Stents. Anticoagulantes. Fondaparinux.
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A ntithrombotic drug therapy, which consists of antiplatelet agents and anticoagulants, together with early invasive risk stratification, constitutes 
an important mainstay in the care of high-risk patients 
with non-ST-segment elevation acute coronary syn-
drome (NSTEACS).1 Increased life expectancy and the 
prevalence of comorbidities, together with the large 
number of new drugs with different anti-ischemic 
action mechanisms, have made it essential for thera-
peutic decisions to strive for a delicate balance of 
the efficacy/safety binomial, which is accomplished 
through careful clinical judgment.
Fondaparinux (Arixtra®, GlaxoSmithKline, Brentford, 
UK) is a synthetic pentasaccharide that indirectly inhibits 
factor Xa through plasma antithrombin. The administra-
tion of a single daily dose of 2.5  mg subcutaneously 
shows a peak plasma concentration within 2 hours 
and a renal clearance half-life of 17 hours. Compared 
with enoxaparin in the randomised trial Fifth Organiza-
tion to Assess Strategies in Acute Ischemic Syndromes 
(OASIS-5) that involved 20,078 patients with NSTEACS, 
fondaparinux promoted a significant reduction of severe 
bleeding at day nine (2.2% vs. 4.1%; P  <  0.001); the 
impact on decreased mortality at day 30 (2.9% vs. 
3.5%; P = 0.02) and after six months (5.8% vs. 6.5%; 
P  =  0.05) is attributed to this finding, favourable to 
fondaparinux.2
However, among the 6,238 patients in the OASIS-5 
study submitted to percutaneous coronary intervention 
(PCI), a higher incidence of thrombus formation was 
observed in the guide catheter of the fondaparinux 
group (0.9% vs. 0.4%); this complication, although 
rare, is associated with higher rates of acute myocar-
dial infarction (AMI) and stroke at 30 days. Intravenous 
supplementation with unfractionated heparin (UFH) at 
the time of PCI was an adequate strategy to prevent this 
phenomenon, a finding that was subsequently validated 
in a large randomised study designed for this purpose.3
The present study aimed to evaluate the efficacy and 
safety of PCI in patients with a diagnosis of NSTEACS 
previously treated with fondaparinux in a ‘real-world’ 
clinical setting.
METHODS
This was a prospective controlled study involving 
consecutive patients who were hospitalised for unstable 
angina or myocardial infarction without ST-segment 
elevation and underwent early invasive stratification 
with PCI indication. The antithrombotic treatment of 
all patients at hospital admission consisted of 2.5  mg 
fondaparinux administered subcutaneously once per 
day, a single oral dose of aspirin of 200 to 300  mg, 
followed by 100  mg/daily, a single 300 to 600  mg 
dose of clopidogrel, followed by 75  mg/daily, or a 
single 180  mg dose of ticagrelor, followed by 90  mg 
twice daily.
After obtaining the arterial access pathway, up to 
5,000 U of UFH were administered through the introducer 
sheath when the radial or ulnar techniques were used 
and 2,500 U of UFH when the femoral technique was 
used. When the coronary angiography was finished and 
PCI was indicated, the patients received supplemental 
intravenous UFH prior to the insertion of the intracoro-
nary guidewire, with a total dose of 85 U/kg or 60 U/
kg when the use of glycoprotein IIb/IIIa inhibitors was 
planned, aiming to achieve an activated coagulation 
time between 250 and 350 seconds. The procedure was 
performed following the recommendations of current 
guidelines.4 The arterial sheath was removed immediately 
after the procedure when the ulnar or radial pathways 
were used; or after two hours, or when the activated 
coagulation time was < 180 seconds when the femoral 
pathway was used.
The primary efficacy endpoint included the oc-
currence of cardiovascular death, AMI, stroke, stent 
thrombosis or emergency coronary artery bypass graft 
(CABG) surgery during the hospitalisation period. The 
primary safety endpoint consisted of severe bleeding, 
vascular complications at the arterial puncture site, abrupt 
occlusion of the target vessel, or catheter thrombosis.
In accordance with the classification of the Bleed-
ing Academic Research Consortium,5 severe bleeding 
was defined as type 3 (3a, bleeding with a decrease 
in haemoglobin ≥  3 and <  5  g/dL or transfusion of 
packed red blood cells; 3b, bleeding with a decrease 
in haemoglobin ≥  5  g/dL or cardiac tamponade or 
bleeding requiring surgical intervention or intravenous 
vasoactive drugs; and 3c, intracranial haemorrhage or 
subcategories confirmed by autopsy, imaging exams or 
lumbar puncture or intraocular bleeding with vision 
impairment) or type 5 (5a, probable fatal bleeding; and 
5b, definite fatal bleeding). Vascular complications at 
the site of the arterial puncture included retroperitoneal 
bleeding, compartment syndrome, hematoma ≥  5  cm, 
pseudoaneurysm, arteriovenous fistula, infection, limb 
ischemia, asymptomatic arterial occlusion, adjacent nerve 
injury or the need for reconstructive vascular surgery. 
Abrupt occlusion of the target vessel was defined as 
thrombolysis in myocardial infarction (TIMI) flow grade 
0–1 during PCI in a coronary artery with previously 
normal anterograde flow (TIMI 3). Catheter thrombosis 
was defined as the presence of newly visible and/or 
angiographic thrombus in the guide-catheter or any 
instruments used during the procedure.
Continuous variables were expressed as the mean 
and standard deviation, and categorical variables were 
expressed as absolute numbers and their percentages. 
RESULTS
From November, 2010 to November, 2011, 800 
patients diagnosed with NSTEACS underwent early in-
vasive stratification. Of these, 317 (39.6%) underwent 
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PCI, of whom 127 (40.1%) used fondaparinux and dual 
antiplatelet therapy. These patients comprised the final 
sample (Figure 1).
The mean age was 62.5  ±  12.4 years. Females 
comprised 24.4% of the study sample; 31.5% of the 
patients had diabetes mellitus (Table 1). Positive myo-
cardial necrosis markers and ECG alterations suggestive 
of ischaemia (ST-segment depression or T-wave inver-
sion >  3  mm) were present in 68% and 89% of the 
sample, respectively, suggesting a high-risk population. 
The procedural characteristics are shown in Table 2. 
PCI immediately after coronary angiography (ad hoc) 
was performed in 78.7% of the cases. The radial access 
was the predominant pathway (95.3%). The left anterior 
descending artery was considered the target vessel in 
51.9% of the procedures, and stents were implanted 
in 97.6% of the arteries. The mean hospital stay was 
3.8  ±  0.6 days, and the duration of fondaparinux use 
was 2.3  ±  0.3 days.
The overall incidence of adverse ischaemic cardio-
vascular events, which was the efficacy endpoint, was 
3.2%. These events were due to one cardiovascular 
death (0.8%) secondary to refractory ventricular fibril-
lation, two periprocedural AMI (1.6%) confirmed by 
elevated creatine kinase MB fraction (CK-MB) >  three 
times the maximum reference value and one (0.8%) 
ischemic stroke (Figure 2). There were no cases of stent 
thrombosis or the need for emergency CABG.
Regarding the safety endpoint, the cumulative 
incidence of events during hospitalisation was 3.2%, 
with one episode of severe bleeding type 3b (0.8%) 
and a decrease in haemoglobin of 5.3  g/dL second-
ary to hematoma in the right upper limb and three 
haematomas (2.4%) >  5  cm of subcutaneous location 
without clinical symptoms as vascular complications in 
the arterial puncture site (Figure 3). There were no cases 
of abrupt vessel occlusion or catheter thrombosis with 
the systematic supplementation of UFH prior to PCI.
DISCUSSION
In patients diagnosed with NSTEACS who under-
went PCI, a strong, consistent, and temporal associa-
tion between the occurrence of severe bleeding and 
ischaemic events, including death, AMI, and stroke, can 
be observed.6 The prognostic impact of a severe bleed-
ing episode is comparable to that of recurrent AMI on 
the subsequent mortality rate.7 Thus, strategies aimed at 
reducing or minimising the complication of maintaining 
n = 190
(UFH/LMWH)
Patients with a diagnosis of NSTE-ACS
November, 2010 to November, 2011
Invasive stratification (n = 800)
Coronary angiography
n = 483
Clinical treatment/CABG
n = 317
Clinical treatment + PCI
n = 127
(fondaparinux)
Figure 1 – Flowchart of patients included in the registry. LMWH = low molecular-weight heparin, UFH = unfractionated heparin, PCI = percutaneous 
coronary intervention, n = number of patients, CABG = coronary artery bypass graft, NSTEACS = non-ST segment elevation acute coronary syndrome. 
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the anti-ischaemic efficacy are important steps in thera-
peutic decision-making.8 Among these strategies, new 
commercially available antithrombotic agents, such as 
fondaparinux, have shown promise in clinical practice 
while also promoting this efficacy and safety profile.2,9,10
In the pre-specified subanalysis of the OASIS-5 study 
involving patients undergoing PCI, the use of fondaparinux 
reduced the risk of severe bleeding at nine days in 54% 
(2.4% vs. 5.1%; P  <  0.00001) of cases, with a similar 
incidence of ischaemic events compared with enoxaparin, 
resulting in a higher net clinical benefit (death, AMI, 
stroke, severe bleeding: 8.2% vs. 10.4%; P  =  0.004).11 
However, finding an increased risk of thrombus forma-
tion in the guide catheter, a condition unfavourable to 
fondaparinux, led to a conservative attitude regarding 
its acceptance in this group of patients.
The observation that UFH supplementation prior 
to PCI reduced the risk of this complication led to 
the randomised Fondaparinux Trial with Unfractioned 
Heparin During Revascularization in Acute Coronary 
Syndromes (FUTURA/OASIS-8), which aimed to determine 
the optimal dose of UFH to be administered during the 
procedure and to determine whether its addition would 
attenuate the benefits achieved with fondaparinux in 
reducing bleeding.3 That study, which involved 2,026 
patients, concluded that a dose of intravenous UFH 
of 85  U/kg guided by the activated coagulation time 
did not increase bleeding and vascular complications 
TABLE 1 
Basal Demographic and Clinical Characteristics
Variables n = 127
Female gender, n (%) 31 (24.4)
Mean age, years 62.5 ± 12.4
Age ≥ 75 years, n (%) 22 (17.3)
Body mass index, kg/m² 27.6 ± 4.8
Diabetes mellitus, n (%) 40 (31.5)
Diabetes mellitus with insulin  
use, n (%) 
8 (6.3)
Systemic arterial hypertension, n (%) 83 (65.4)
Dyslipidemia, n (%) 89 (70.1)
Smoking, n (%) 45 (35.4)
Family history of coronary  
failure, n (%)
29 (22.8)
Chronic renal failure, n (%) 4 (3.1)
Previous acute myocardial  
infarction, n (%) 
16 (12.6)
Previous percutaneous coronary 
intervention, n (%) 
17 (13.4)
Previous CABG, n (%) 6 (4.7)
Previous cerebrovascular  
accident, n (%) 
4 (3.1)
Antithrombotic therapy, n (%)
 Fondaparinux 127 (100)
 Aspirin 127 (100)
 Clopidogrel 107 (84.3)
 Ticagrelor 20 (15.7)
n = number of patients.
TABLE 2 
Characteristics of the Procedures
Variables n = 127
Percutaneous coronary intervention 
ad hoc, n (%)
100 (78.7)
Elective percutaneous coronary 
intervention, n (%)
27 (21.3)
Radial access, n (%) 121 (95.3)
Ulnar access, n (%) 4 (3.1)
Femoral access, n (%) 2 (1.6)
Crossover rate, n (%) 1 (0.8)
5 F guide-catheter, n (%) 4 (3.1)
6 F guide-catheter, n (%) 123 (96.9)
Number of catheters 1.2 ± 0.4
Duration of procedure, minutes 28.9 ± 13.4
Duration of fluoroscopy, minutes 7.3 ± 4.4
Target-vessel, n (%)  
 Let main coronary artery 4 (3.1)
 Anterior descending artery 66 (51.9)
 Right coronary artery 33 (25.9)
 Circumflex artery 32 (25.2)
Stent implant, n (%) 124 (97.6)
Number of stents per patient 1.2 ± 0.6
Drug-eluting stent, n (%) 21 (16.5)
Bare-metal stent, n (%) 106 (83.5)
Pre-dilation, n (%) 49 (38.6)
Post-dilation, n (%) 68 (53.5)
Glycoprotein IIb/IIIa inhibitor, n (%) 31 (24.4)
Sedation, n (%) 58 (45.7)
Angiographic success, n (%) 125 (98.4)
n = number of patients.
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compared to a fixed dose of 50  U/kg, with an almost 
null rate (0.1%) of guide catheter thrombosis and a 
tendency towards the reduction of ischaemic events.
Based on the results of these studies, treatment of 
NSTEACS with fondaparinux plus UFH when PCI is 
necessary has been considered the anticoagulant strategy 
with better efficacy and a better safety profile, garner-
ing a class I recommendation and a level of evidence 
A, according to a recent European guideline.1 However, 
the use of stringent and often restrictive inclusion and 
exclusion criteria in randomised trials gives this se-
lected population a status of non-representativeness in 
daily clinical practice. In this context, consecutive and 
controlled registries still provide an accurate picture of 
contemporary practice, and are sources of information that 
allow critical analysis when applying a therapeutic tool.
The present sample had a mean age >  60 years, 
of which 17% were aged >  75 years. Subjects had a 
high prevalence of positive myocardial necrosis mark-
ers and ischaemic electrocardiographic alterations. The 
antithrombotic drug therapy consisted of systematically 
administered fondaparinux and dual antiplatelet therapy. 
This therapy added to early invasive stratification and 
promoted a decrease of in-hospital incidence of isch-
aemic adverse cardiovascular events and episodes of 
severe bleeding. A low rate of bleeding complications 
was observed, which was dissimilar from the findings 
of major international records, which showed a rate of 
near 9% in a sample with similar risk.12,13 This finding 
is attributed to the fact that, in addition to the rou-
tine use of fondaparinux, the radial or ulnar accesses 
were the preferred pathways when performing invasive 
coronary procedures, which composed 98.4% of the 
cases. Consistent evidence indicates that the choice 
of radial access rather than femoral access, especially 
when the surgeon has experience with the technique, 
promotes the reduction of vascular complications, death, 
AMI, stroke, and major bleeding nonrelated to CABG 
surgery.14–16 Besides, by instituting supplemental UFH 
therapy immediately after the arterial sheath is placed, 
in addition to complementing the dose because of the 
need for PCI, no thrombotic complications related to 
the procedure or instruments were observed, and a 
higher risk of bleeding was thus avoided.
Study limitations
The limitations of the present study included its 
observational nature, the absence of a control group, 
using alternative anticoagulant treatment, the limited 
number of patients (as it represents the authors’ initial 
report on their experience with a new drug), and the 
lack of follow-up with patients after hospital discharge 
once the high cumulative mortality at one year in this 
clinical setting was known.17
CONCLUSIONS
In patients with NSTEACS, i.e., those representative 
of the ‘real world’ who were previously treated with 
fondaparinux, the adjuvant infusion of UFH before PCI 
eliminated the risk of thrombus formation in the catheter 
due to its low rate of adverse ischaemic cardiovascular 
events and severe haemorrhagic complications.
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